SureTrader Advertisement
Home > Boards > US Listed > Biotechs >

MannKind Corp. (MNKD)

Add MNKD Price Alert      Hide Sticky   Hide Intro
Moderator: conix, steez, Phaeton, $Pistol Pete$
Search This Board:
Last Post: 6/29/2016 10:21:22 AM - Followers: 353 - Board type: Free - Posts Today: 2


About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients.

AFREZZA® (pronounced uh-FREZZ-uh) is a rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes. AFREZZA was approved by the FDA in 2014. MannKind has a global licensing agreement with Sanofi for the development and commercialization of AFREZZA. Sanofi is responsible for global commercial, regulatory and development activities and. MannKind manufactures AFREZZA at its manufacturing facility in Danbury, CT.

AFREZZA utilizes our proprietary Technosphere® formulation technology , which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded.  We believe Technosphere represents a versatile drug delivery platform that may allow pulmonary administration of certain drugs that currently require administration by injection, such as GLP-1. Pulmonary administration provides convenience for the patient and we believe a major advantage of drugs inhaled as Technosphere formulations is that they have been shown to be absorbed very rapidly into the arterial circulation, essentially mimicking intra-arterial administration. MannKind is also developing other inhalation technologies, including an innovative line of patient-focused, breath-activated, dry powder inhalers and inhalation profiling to characterize patient inhalation.

- See more at:


Board of Directors

Alfred E. Mann

Alfred E. Mann has been one of our directors since April 1999, our Chairman of the Board since December 2001 and our Executive Chairman since January 2015. He also served as our Chief Executive Officer from October 2003 until January 2015.  Mr. Mann has founded and largely funded 14 companies in his career.  Nine were acquired at an overall total of almost $8 billion, and three companies became public.  In addition to MannKind, he is currently involved with:

• Bioness, which develops and manufactures systems to address neural deficits and to restore controlled function of paralyzed limbs;
• Second Sight, which is developing a visual prosthesis to restore sight to the blind; 
• IncuMed, which is developing novel percutaneous seals for various applications; 
• PerQFlo, which is developing drug delivery systems; and
• RoundTrip, which is developing location and identification technology.

In 1993, Mr. Mann founded and served as Chairman and Chief Executive Officer of MiniMed Inc. until August 2001 when it was acquired by Medtronic, Inc.  Medtronic MiniMed develops, manufactures and distributes microinfusion systems and continuous glucose monitoring systems that have revolutionized the treatment of Type 1 diabetes.  Mr. Mann founded and funded Medical Research Group (MRG), a developer of an artificial pancreas.  MRG was also acquired by Medtronic in 2001.  Mr. Mann also founded and served as the Chairman of the Board and Chief Executive Officer of Advanced Bionics Corporation from its founding in 1993 until it was acquired by Boston Scientific Corporation in 2004.  Advanced Bionics developed neurostimulation devices for various neural deficits, including cochlear stimulators.  Previously, Mr. Mann founded and was Chairman of the Board and CEO of Pacesetter Systems, Inc., which developed, manufactured and distributed cardiac pacemakers, from 1972 until 1985 when it was acquired by Siemens, AG.  From 1985 to September 1992, Mr. Mann continued to serve as Chairman and CEO of the successor company, Siemens-Pacesetter, Inc., Pacesetter is now the Cardiac Rhythm Management unit of St. Jude Medical.  Prior to 1972, he was President of Spectrolab, an electro-optical and aerospace systems company, and Heliotek, a semiconductor and electro-optical components manufacturer.  Mr. Mann founded these companies in 1956 and 1960, respectively, sold them to Textron Inc. in 1960 and continued to lead them until 1972, when he left for Pacesetter.  They are now part of the Boeing Company.
Mr. Mann founded and endowed, and from 1985 until 2006 served as Chairman of the Board of Trustees of The Alfred Mann Foundation, a nonprofit research organization devoted to development of advanced medical products in a variety of fields.  Mr. Mann is currently Chairman of the Board of Trustees of the Alfred Mann Institutes at the University of Southern California, Purdue University, and The Technion Institute (Israel), all of these medical research foundations founded and endowed principally by Mr. Mann.  He also serves as a Trustee for the University of Southern California, as a member of the Board of Overseers of the Keck USC School of Medicine, and as the Chairman of the Southern California Biomedical Council, a nonprofit association dedicated to the fostering of the bio-medical industry in the Los Angeles Metropolitan area.  Alfred Mann also serves as a Director of the Nevada Cancer Institute.
Mr. Mann holds B.A. and M.S. degrees in physics from the University of California, Los Angeles and honorary doctorate degrees from the University of Southern California, The Johns Hopkins University, Western University and the Technion Institute (Israel).  Mr. Mann is also a member of the National Academy of Engineering.

Ronald Consiglio


Ronald J. Consiglio has been one of our directors since October 2003. Since 1999, Mr. Consiglio has been the managing director of Synergy Trading, a securities-trading partnership. From 1999 to 2001, Mr. Consiglio was Executive Vice President and Chief Financial Officer of Trading Edge, Inc., a national automated bond-trading firm. From January 1993 to 1998 Mr. Consiglio served as Chief Executive Officer of Angeles Mortgage Investment Trust, a publicly traded Real Estate Investment Trust. His prior experience includes serving as Senior Vice President and Chief Financial Officer of Cantor Fitzgerald & Co. and as a member of its board of directors. Mr. Consiglio has served as a member of the board of trustees for the Metropolitan West Funds since 2003. Mr. Consiglio is a certified public accountant and holds a bachelor’s degree in accounting from California State University at Northridge  A good forum for discussion on Mankind

MannKind Corporation, a development stage company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diabetes and cancer. Its lead investigational product candidate, the Technosphere Insulin System, is in phase III clinical trials in the United States, Europe, and Latin America for the treatment of diabetes. This dry powder therapy consists of Technosphere particles onto which insulin molecules are loaded. These loaded particles are then aerosolized and inhaled into the deep lung using its proprietary MedTone inhaler. The company is also developing therapies for the treatment of solid tumor cancers. The lead product candidate in this program, MKC1106-PP, which is in phase I clinical trial is intended for the treatment of various solid-tumor cancers, including ovarian, colorectal, pancreatic, renal, breast, and prostate carcinomas and melanoma. MannKind was founded in 1991 and is headquartered in Valencia, CA.;;




  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
MNKD News: Biotechnology Equities at a Glance -- MannKind, bluebird bio, OncoGenex Pharma, and Hevat Biologics 06/27/2016 08:25:00 AM
MNKD News: MannKind Announces Late-Breaking Data Reinforcing Faster Onset and Shorter Duration of Action Compared to Mealtime Insulins 06/12/2016 03:00:00 PM
MNKD News: MannKind Announces Collaboration with JDRF 06/10/2016 09:00:00 AM
MNKD News: Current Report Filing (8-k) 05/24/2016 04:27:18 PM
MNKD News: Statement of Changes in Beneficial Ownership (4) 05/18/2016 08:02:16 AM
#18992   Looking good today dmcc2087 06/29/16 10:21:22 AM
#18507  Sticky Note Top Equity Manager Still believes in MannKind. Phaeton 06/01/16 12:36:23 PM
#16574  Sticky Note $MNKD ~ MannKind Corp. due diligence report $Pistol Pete$ 12/18/15 01:14:52 AM
#18991   Profit and loss based on new scrips Per year TREND1 06/29/16 05:12:27 AM
#18990   Mankind isn't going anywhere but up ! Brentpdc 06/28/16 10:37:59 PM
#18989   There is still hope. TREND1 06/28/16 09:15:20 PM
#18988   Sad to see a promising technology failing to Spicknspan 06/28/16 08:56:56 PM
#18987   by Harlan Bretz TREND1 06/28/16 08:31:04 PM
#18986   Strong close looking solid MNKD dmcc2087 06/28/16 06:02:05 PM
#18985   Great consolidation dmcc2087 06/28/16 04:12:45 PM
#18984   MNKD 2 HOUR ....Some times gives better picture. TREND1 06/28/16 11:48:48 AM
#18983   MNKD 1 HOUR .... Looks like a triangle..... TREND1 06/28/16 11:21:16 AM
#18982   Hypi Have sent email to my broker. TREND1 06/28/16 10:20:51 AM
#18981   Time to see a higher high this week dmcc2087 06/28/16 09:50:56 AM
#18980   Just added another 10,000 at 1.15 20,000 at dmcc2087 06/28/16 09:50:29 AM
#18979   nice i got back in at steez 06/28/16 09:50:00 AM
#18978   $1.15 back to see a new high dmcc2087 06/28/16 09:47:47 AM
#18977   Reload reload let's goooo dmcc2087 06/28/16 09:47:31 AM
#18976   Back in for 10,000 at 1.13 dmcc2087 06/28/16 09:36:42 AM
#18975   will call my broker after things settle down. TREND1 06/28/16 09:32:41 AM
#18974   Article is from 2013 TRLLR Hypi 06/28/16 07:19:14 AM
#18973   $MNKD MannKind Announces Late-Breaking Data Reinforcing Faster Onset $Pistol Pete$ 06/27/16 10:48:45 PM
#18972   If you used vix to hedge, margin increased TREND1 06/27/16 09:45:16 PM
#18971   *****LEARN problems problems TREND1 06/27/16 09:21:37 PM
#18970   I like the chances with this one too. TREND1 06/27/16 07:12:42 PM
#18969   Probability of BK is like any biotech company, Hypi 06/27/16 07:09:22 PM
#18968   I thought you were funny too. TREND1 06/27/16 05:34:55 PM
#18967   Pumper there TREND1 06/27/16 05:32:47 PM
#18966   Lmfao dmcc2087 06/27/16 04:53:27 PM
#18964   Any one seen this site before ? TREND1 06/27/16 04:26:31 PM
#18963   No trade shows, conferences or earnings release in Hypi 06/27/16 03:23:22 PM
#18962   Hypi The only big news on this board was TREND1 06/27/16 02:04:35 PM
#18961   I was fortunate and lucky as I bought Hypi 06/27/16 01:28:58 PM
#18960   IBB and MNKD DAY TREND1 06/27/16 12:33:27 PM
#18959   Good for you ... TREND1 06/27/16 11:46:04 AM
#18958   Don't need one . Bought in at a Danburydude 06/27/16 11:44:27 AM
#18957   Hypi I have found that CASH is the best TREND1 06/27/16 11:41:59 AM
#18956   Not at all and we have now seen Hypi 06/27/16 11:16:04 AM
#18955   Glad to see you are learning. TREND1 06/27/16 11:11:45 AM
#18954   back in 1.16 holding ma 50 steez 06/27/16 10:54:27 AM
#18953   *****MannKind And The Importance Of Modeling TREND1 06/27/16 10:48:32 AM
#18952   Was the drop in short interest telling us TREND1 06/27/16 10:44:37 AM
#18951   I took profits today at 1.19 looking to dmcc2087 06/27/16 10:44:20 AM
#18950   We have or 10. a day spread back kugel 06/27/16 10:38:59 AM
#18949   MNKD Short Interest Is Down For some time now, dmcc2087 06/27/16 09:15:05 AM
#18948   MannKind Corp. (NASDAQ: MNKD) saw its short interest dmcc2087 06/27/16 09:08:18 AM
#18947   Short interest going down is a great sign dmcc2087 06/27/16 09:00:00 AM
#18946   2 new great articles out on MNKD dmcc2087 06/27/16 08:59:48 AM
#18945   So what is your mental stop for your TREND1 06/27/16 07:55:27 AM
#18944   Say what ? A mental stop loss that Danburydude 06/26/16 11:42:45 PM
#18943   MNKD WEEKLY 5 EMA X 20 EMA = BUY/SELL TREND1 06/26/16 09:50:42 PM
#18942   This week dmcc2087 06/26/16 06:55:15 PM